Stock Market Update - November 28, 2025
Today's stock market saw some significant movers. Here's a breakdown of 5 stocks that caught our attention:
1. SMX - SMX (Security Matters) Public Limited Company
Price: $60.18 | Change: +245.86% ($42.78)
SMX captivated investors with an eye-popping 245.86% gain, primarily driven by exciting developments around November 29, 2025. The company unveiled its groundbreaking molecular verification technology and announced six significant partnerships, generating substantial attention at the DMCC Precious Metals Conference in Dubai.
This innovative system embeds unique, permanent chemical signatures into various materials, from aerospace metals to gold, enabling unparalleled traceability and proof of origin. This breakthrough addresses critical industry needs for transparency, anti-counterfeiting, and sustainability across supply chains, from "ore to orbit." The market's enthusiastic reaction, including a surge of over 200% on November 28th, highlights strong investor confidence in SMX's potential to redefine industry standards and achieve rapid commercial adoption.
2. VEEE - Twin Vee Powercats Co.
Price: $2.685 | Change: +50.84% ($0.905)
VEEE recently saw an impressive 50.84% gain, primarily fueled by exciting news for boat buyers. The federal "Big Beautiful Bill" now allows for 100% first-year depreciation on vessels used 50% or more for business purposes. This creates a significant incentive for entrepreneurs and businesses, allowing them to deduct the entire cost of a qualifying boat in the year of purchase.
Twin Vee Powercats is strategically positioning its 24-foot to 40-foot models, perfect for business applications like fishing charters or commercial transport, to help buyers take advantage of these substantial 2025 tax benefits. This major tax incentive is further bolstered by other recent positive developments, including an 18% increase in Q3 net sales and the launch of their Bahama Boat Works line, all contributing to increased investor confidence in the company.
3. KTTA - Pasithea Therapeutics Corp.
Price: $1.47 | Change: +38.68% ($0.41)
KTTA just soared 38.68%! Pasithea Therapeutics Corp. saw a significant bump after announcing the pricing of a $60 million public offering. This new funding, backed by leading healthcare investors, is set to extend the company's cash runway through the first half of 2028, providing important financial stability for its operations and research.
Adding to the positive sentiment were recent clinical developments for their lead drug candidate, PAS-004. These included a $1 million grant to study the drug for ALS, along with favorable safety results from an early-stage trial in cancer patients and promising interim data showing reduced tumor size.
The combination of secured financing, which provides a longer runway for operations, and positive news regarding their promising drug candidate, appears to have significantly boosted investor confidence in the company's future prospects.
4. WBUY - WEBUY GLOBAL Ltd. Ordinary Shares
Price: $2.07 | Change: +38.00% ($0.57)
WBUY saw its shares jump by a notable 38.00% recently, primarily thanks to a strategic financial move by WEBUY GLOBAL Ltd. The company announced it had settled a significant debt of over $614,000 in late November 2025.
Instead of paying cash, Webuy Global issued Class A ordinary shares directly to its creditors. This conversion of debt into equity means the company's financial books look stronger, as a significant liability is removed without using cash reserves.
What's particularly interesting is that this transaction resulted in the creditors' designated recipient acquiring approximately 20.96% of Webuy's outstanding shares. This shift in ownership structure, alongside the debt reduction, is why investors reacted positively to the news.
5. VRCA - Verrica Pharmaceuticals Inc.
Price: $9.1 | Change: +35.62% ($2.39)
VRCA:NASDAQ recently soared with an impressive 35.62% gain, driven by a strategic financial maneuver. Verrica Pharmaceuticals Inc. announced a significant private placement financing, securing approximately $50 million. This crucial capital injection was primarily used to fully retire their existing $50 million debt facility, essentially clearing a major financial overhang.
This smart move not only eliminated a substantial debt but also provided extra funds for operations, extending the company's cash runway into mid-2027. The financing was backed by key investors like Caligan Partners LP and PBM Capital, with Caligan gaining a board seat. This de-risks Verrica's balance sheet and provides more flexibility to advance its drug pipeline, including treatments for molluscum contagiosum and basal cell carcinoma.
Further signaling confidence, several company executives, including the CEO, made notable stock purchases around the time of the announcement. This internal endorsement often highlights a strong belief in the company's future direction following such a pivotal financial restructuring.
This analysis was generated using AI and real-time stock data. Always do your own research before making investment decisions.